Common Cardiac Effects Reported with Lacosamide
Lacosamide, an antiepileptic drug, primarily affects cardiac sodium channels, which can lead to conduction abnormalities. The most typical effects include PR interval prolongation on ECG, seen in up to 42% of patients in clinical trials at doses of 400 mg/day, and atrioventricular (AV) block (first-, second-, or third-degree) in about 0.4-1% of cases.[1][2] These changes are dose-dependent and usually asymptomatic but require ECG monitoring, especially in patients with pre-existing conduction issues.
Why Does Lacosamide Affect the Heart?
It selectively enhances slow inactivation of voltage-gated sodium channels in the heart, slowing conduction velocity. This differs from fast sodium channel blockers like carbamazepine, resulting in fewer ventricular proarrhythmias but higher risk of bradyarrhythmias.[1][3] Animal studies and human ECG data confirm reduced His-Purkinje conduction without significant QT prolongation (mean QTc increase <2 ms).[2]
What Happens in Overdose or High-Risk Patients?
In overdose, effects escalate to severe bradycardia, wide QRS complex (>120 ms), and hypotension; case reports describe QRS widening reversible with sodium bicarbonate.[1][4] Patients over 75 years or with baseline conduction delays face 10-fold higher AV block risk. Bundle branch blocks occur in 1-5%, often reversible upon discontinuation.[2]
How Does It Compare to Other Antiepileptics?
Unlike lamotrigine (milder PR prolongation) or levetiracetam (negligible cardiac effects), lacosamide shows stronger PR effects but lower arrhythmia risk than phenytoin. No increased sudden cardiac death signal in post-marketing data.[1][3]
Monitoring and Management Guidelines
FDA labeling recommends baseline and periodic ECGs for patients with heart disease; hold if PR >280 ms or second-degree AV block develops. Avoid in severe conduction disorders or with drugs prolonging PR (e.g., beta-blockers).[1][2] European guidelines echo this for epilepsy patients with cardiac history.[5]
[1]: FDA Label for Vimpat (lacosamide)
[2]: SPILF Recommendations on Lacosamide Cardiac Safety
[3]: Voltage-Gated Sodium Channel Review
[4]: Lacosamide Overdose Cases
[5]: EMA Assessment Report